Postremission cytopenia management in patients with acute
myeloid leukemia treated with venetoclax and azacitidine in
VIALE-A

J 2022

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

PRATZ, Keith W, Courtney D DINARDO, Dominik SELLESLAG, Junmin LI, Kazuhito YAMAMOTO et. al.

Základní údaje

Originální název

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

Autoři

PRATZ, Keith W (garant), Courtney D DINARDO, Dominik SELLESLAG, Junmin LI, Kazuhito YAMAMOTO, Marina KONOPLEVA, Don STEVENS, Hagop KANTARJIAN, Fabiola TRAINA, Adriano VENDITTI, Jiří MAYER (203 Česká republika, domácí), Melissa MONTEZ, Huan JIN, Yinghui DUAN, Deanna BRACKMAN, Jiuhong ZHA, Jalaja POTLURI, Michael WERNER a Brian A JONAS

Vydání

American Journal of Hematology, Hoboken, John Wiley & Sons, 2022, 0361-8609

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 12.800

Kód RIV

RIV/00216224:14110/22:00128097

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/ajh.26692

UT WoS

000854058000001

Klíčová slova anglicky

postremission cytopenia management; acute myeloid leukemia; venetoclax; azacitidine

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 18. 1. 2023 13:29, Mgr. Tereza Miškechová

Anotace

V originále

The phase 3 VIALE-A study (NCT02993523) of venetoclax (Ven) + azacitidine (Aza) demonstrated significantly improved median overall survival (OS; 14.7 months) compared with placebo (Pbo) + Aza in patients with newly diagnosed acute myeloid leukemia (AML) who were aged ≥75 years or ineligible for intensive chemotherapy. The study protocol recommended dosing schedule modification following remission to mitigate hematologic adverse events (AEs; Figure 1A); these occurred in 83% of patients in the Ven + Aza arm. This post hoc analysis of VIALE-A evaluated the frequency and management of postremission cytopenia events, Ven exposure-response relationship with postremission cytopenias, and outcomes when dosing schedule modifications were required for grade 4 cytopenias.

Citovat

PRATZ, Keith W, Courtney D DINARDO, Dominik SELLESLAG, Junmin LI, Kazuhito YAMAMOTO, Marina KONOPLEVA, Don STEVENS, Hagop KANTARJIAN, Fabiola TRAINA, Adriano VENDITTI, Jiří MAYER, Melissa MONTEZ, Huan JIN, Yinghui DUAN, Deanna BRACKMAN, Jiuhong ZHA, Jalaja POTLURI, Michael WERNER a Brian A JONAS. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. American Journal of Hematology. Hoboken: John Wiley & Sons, 2022, roč. 97, č. 11, s. "E416"-"E419", 4 s. ISSN 0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.26692.

@article{2247608,
   author = {Pratz, Keith W and DiNardo, Courtney D and Selleslag, Dominik and Li, Junmin and Yamamoto, Kazuhito and Konopleva, Marina and Stevens, Don and Kantarjian, Hagop and Traina, Fabiola and Venditti, Adriano and Mayer, Jiří and Montez, Melissa and Jin, Huan and Duan, Yinghui and Brackman, Deanna and Zha, Jiuhong and Potluri, Jalaja and Werner, Michael and Jonas, Brian A},
   article_location = {Hoboken},
   article_number = {11},
   doi = {http://dx.doi.org/10.1002/ajh.26692},
   keywords = {postremission cytopenia management; acute myeloid leukemia; venetoclax; azacitidine},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A},
   url = {https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26692},
   volume = {97},
   year = {2022}
}

TY  - JOUR
ID  - 2247608
AU  - Pratz, Keith W - DiNardo, Courtney D - Selleslag, Dominik - Li, Junmin - Yamamoto, Kazuhito - Konopleva, Marina - Stevens, Don - Kantarjian, Hagop - Traina, Fabiola - Venditti, Adriano - Mayer, Jiří - Montez, Melissa - Jin, Huan - Duan, Yinghui - Brackman, Deanna - Zha, Jiuhong - Potluri, Jalaja - Werner, Michael - Jonas, Brian A
PY  - 2022
TI  - Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A
JF  - American Journal of Hematology
VL  - 97
IS  - 11
SP  - "E416"-"E419"
EP  - "E416"-"E419"
PB  - John Wiley & Sons
SN  - 03618609
KW  - postremission cytopenia management
KW  - acute myeloid leukemia
KW  - venetoclax
KW  - azacitidine
UR  - https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26692
N2  - The phase 3 VIALE-A study (NCT02993523) of venetoclax (Ven) + azacitidine (Aza) demonstrated significantly improved median overall survival (OS; 14.7 months) compared with placebo (Pbo) + Aza in patients with newly diagnosed acute myeloid leukemia (AML) who were aged ≥75 years or ineligible for intensive chemotherapy. The study protocol recommended dosing schedule modification following remission to mitigate hematologic adverse events (AEs; Figure 1A); these occurred in 83% of patients in the Ven + Aza arm. This post hoc analysis of VIALE-A evaluated the frequency and management of postremission cytopenia events, Ven exposure-response relationship with postremission cytopenias, and outcomes when dosing schedule modifications were required for grade 4 cytopenias.
ER  -

PRATZ, Keith W, Courtney D DINARDO, Dominik SELLESLAG, Junmin LI, Kazuhito YAMAMOTO, Marina KONOPLEVA, Don STEVENS, Hagop KANTARJIAN, Fabiola TRAINA, Adriano VENDITTI, Jiří MAYER, Melissa MONTEZ, Huan JIN, Yinghui DUAN, Deanna BRACKMAN, Jiuhong ZHA, Jalaja POTLURI, Michael WERNER a Brian A JONAS. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. \textit{American Journal of Hematology}. Hoboken: John Wiley \&{} Sons, 2022, roč.~97, č.~11, s.~''E416''-''E419'', 4 s. ISSN~0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.26692.

Podrobný výpis o publikaci